United States-based Viriom Inc announced yesterday that it has started the first phase one clinical trial of the long-acting nanoformulation of VM1500A in HIV-uninfected volunteers, it was reported yesterday.
This trial is designed to assess the safety and pharmacokinetics of VM1500A once monthly dosing in up to 36 HIV-uninfected volunteers in a single site clinical trial in Moscow, Russia. Animal studies of VM1500A long acting injectable (VM-1500A-LAI) have indicated an excellent pharmacokinetic profile suggesting feasibility of once monthly or once quarterly dosing to achieve effective antiviral target exposure.
The company is assessing intramuscular and subcutaneous injectable formulations of VM-1500A-LAI.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results